Yahoo · Sep 28, 2026
What Bavarian Nordic’s next CEO is up against
The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.
NYSE · AZN
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
$166.58
Down-$0.09 (-0.06%)
Updated Sep 28, 2026, 4:17 PM
SID Score
7.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 279.95B
- P/E ratio
- 33.06
- Dividend yield
- 0.92%
- 52-week range
- $72.90 – $212.71
- Volume
- 2.07M
- Avg. volume
- 5.47M
Price performance · AZN
AZN price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Sep 25, 2026
AZN closed at $166.58 after 19 trading sessions, up 2.74% for the selected period.
- Last close
- $166.58
- Period change
- +2.74%
- Period low
- $156.94
- Period high
- $168.37
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $166.16 | $166.81 | $164.60 | $166.58 | 2.07M |
| Sep 24, 2026 | $162.91 | $166.25 | $162.91 | $164.56 | 3.19M |
| Sep 23, 2026 | $166.58 | $167.59 | $163.33 | $163.33 | 2.36M |
| Sep 22, 2026 | $167.84 | $169.35 | $166.74 | $168.37 | 2.31M |
| Sep 21, 2026 | $168.45 | $169.00 | $167.11 | $168.10 | 2.94M |
| Sep 18, 2026 | $167.15 | $167.83 | $165.54 | $166.08 | 3.06M |
| Sep 17, 2026 | $164.59 | $166.29 | $164.295 | $166.14 | 3.81M |
| Sep 16, 2026 | $164.21 | $165.42 | $162.02 | $162.89 | 3.86M |
| Sep 15, 2026 | $161.42 | $163.90 | $160.71 | $161.85 | 2.94M |
| Sep 14, 2026 | $164.08 | $164.55 | $162.14 | $163.78 | 3.09M |
| Sep 11, 2026 | $161.43 | $161.51 | $158.13 | $160.17 | 2.23M |
| Sep 10, 2026 | $157.68 | $160.30 | $157.23 | $159.64 | 2.94M |
| Sep 9, 2026 | $158.31 | $159.1301 | $156.74 | $156.94 | 3.87M |
| Sep 8, 2026 | $163.96 | $163.96 | $159.40 | $160.04 | 5.15M |
| Sep 4, 2026 | $162.82 | $163.78 | $161.13 | $162.70 | 3.07M |
| Sep 3, 2026 | $165.64 | $165.74 | $162.24 | $164.77 | 2.43M |
| Sep 2, 2026 | $162.54 | $164.69 | $160.87 | $161.63 | 3.3M |
| Sep 1, 2026 | $163.66 | $164.24 | $161.385 | $162.47 | 2.6M |
| Aug 31, 2026 | $162.70 | $163.75 | $161.95 | $162.13 | 3.07M |
Latest AZN news
The latest Smart Investors Daily articles mentioning AZN.
Stock researchCompany · Overview
AZN research
Overview
Company profile and research snapshot.
Company profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $102.67
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Berenberg Bank | Buy | — |
| Jun 26, 2026 | Deutsche | Sell | — |
| Jun 26, 2026 | Jefferies | Buy | — |
| Jun 11, 2026 | Deutsche | Sell | — |
| Jun 9, 2026 | Jefferies | Buy | — |
News briefing
Generated Sep 28, 2026, 3:06 PM
Why Is AZN Down Today?
AstraZeneca shares declined 0.31% today, closing down $0.52, as the broader healthcare sector experienced modest gains in afternoon trading. Despite positive sector momentum, AZN underperformed its peer group, suggesting stock-specific headwinds or profit-taking may be offsetting positive healthcare tailwinds.
Bottom line: AstraZeneca's modest 0.31% decline today appears to reflect profit-taking rather than any fundamental deterioration, as the broader healthcare sector gains traction. Investors should monitor whether AZN can recapture sector momentum and watch for upcoming catalysts—such as pipeline updates or clinical data—to reignite positive momentum and justify renewed accumulation.
Yahoo · Sep 25, 2026
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the
Yahoo · Sep 25, 2026
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street
Yahoo · Sep 25, 2026
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
AI research layers
Interpretive context generated from the platform’s current data sources.
AstraZeneca PLC Stock Performance
AstraZeneca PLC shares traded at $166.58, reflecting a modest 0.19% gain over the past month but a notable 11.59% decline over the trailing three-month period, per SID market data. Despite the recent quarterly weakness, the stock has delivered a strong 119.27% return over the past twelve months, significantly outperforming the broader healthcare sector. Technically, AZN trades above both its 50-day moving average of $164.03 and its 200-day moving average of $165.45, suggesting the stock has reclaimed near-term support levels. The 14-day relative strength index registers at 56.6, indicating neutral momentum with no overbought or oversold conditions. AstraZeneca's beta of 0.168, according to Massive/Polygon data, reflects exceptionally low volatility relative to the broader market. Average daily trading volume stands at approximately 5.47 million shares, supporting adequate liquidity for the company's $279.9 billion market capitalization.
AstraZeneca PLC Valuation Analysis
AstraZeneca PLC currently trades at a price-to-earnings ratio of 33.06, placing it at a premium relative to many large-cap pharmaceutical peers, per SID market data. The PEG ratio stands at 4.53, suggesting the stock's valuation substantially exceeds its expected earnings growth rate, according to SEC filings and consensus estimates. The price-to-book ratio of 6.24 further underscores the premium investors assign to AstraZeneca's oncology and biopharmaceutical pipeline. The company offers a dividend yield of 1.56%, providing a modest income component for shareholders. With a market capitalization of approximately $279.9 billion, AstraZeneca ranks among the largest global pharmaceutical companies by market value. The elevated valuation multiples reflect the company's strong revenue trajectory in key therapeutic areas, though the PEG ratio indicates that current pricing may already incorporate significant forward growth expectations within the healthcare sector landscape.
Smart Money Activity for AZN
AstraZeneca PLC registers a composite smart money score of 58 out of 100 with a neutral overall signal, per SID market data. Institutional ownership activity scores a perfect 25 out of 25, indicating robust positioning among major fund managers and suggesting strong institutional conviction in the company's long-term fundamentals, according to 13F institutional filings. Insider activity scores 12.5 out of 25, with three insider transactions recorded over the past 90 days — all of which were purchases, with zero insider sales reported during the period, per SEC Form 4 filings. This unanimously bullish insider buying pattern is a constructive signal. Congressional trading activity scores 12 out of 25, reflecting moderate legislative interest. Dark pool activity registers at a relatively low 8.8 out of 25, suggesting limited off-exchange institutional block trading in recent weeks. The divergence between strong institutional holdings and subdued dark pool activity presents a mixed but modestly positive smart money profile for AZN shareholders.
AstraZeneca PLC Earnings Outlook
AstraZeneca PLC has delivered consecutive significant earnings surprises in its two most recently reported quarters, according to company earnings reports. The company posted earnings of $2.63 per share against a consensus estimate of $1.52, representing a positive surprise of $1.11, or approximately 73%. In the following reported quarter, AstraZeneca earned $2.58 per share versus the $1.53 estimate, delivering another substantial beat of $1.05 per share. These back-to-back outperformances underscore strong operational execution across the company's oncology, cardiovascular, and rare disease portfolios. Looking ahead, analyst estimates project earnings of $1.75 per share for the upcoming quarter with results expected on April 28, 2026, and $1.44 per share for the subsequent quarter reporting on July 28, 2026. The pattern of meaningful earnings beats suggests analysts may be conservatively modeling AstraZeneca's growth trajectory, though future results remain subject to pipeline developments and regulatory outcomes.
Wall Street Analyst Ratings for AZN
Wall Street analyst sentiment on AstraZeneca PLC remains divided, per recent analyst reports and SID consensus data. Berenberg Bank reiterated a Buy rating on July 13, 2026, reflecting confidence in the company's pipeline and commercial momentum. Jefferies has also maintained a Buy rating, reiterating the call on both June 26 and June 9, 2026, signaling sustained bullish conviction. In contrast, Deutsche Bank stands as a notable bear, reiterating a Sell rating on both June 26 and June 11, 2026, suggesting concerns about valuation or specific risk factors at current price levels. The polarized coverage between these three firms highlights meaningful disagreement among institutional research desks regarding AstraZeneca's risk-reward profile. With the stock trading at a P/E of 33.06 and a PEG ratio of 4.53, the valuation debate appears central to the divergent ratings. Investors face a split consensus where both bullish and bearish cases carry institutional credibility.
